ScholarDeck

Cohort studyLife (Basel, Switzerland) · 2026

Predictors of 90-Day Mortality and the Association of Reperfusion Therapy with 90-Day Mortality in Intermediate-High and High-Risk Pulmonary Embolism: A Real-World Multidisciplinary Cohort Study.

Özgür Batum, Merve Ayık Türk, Yelda Varol … Sibel Doruk

Internal MedicineCohort study

Reperfusion therapy independently associated with lower 90-day mortality in high-risk pulmonary embolism

Predictors of 90-Day Mortality and the Association of Reperfusion Therapy with 90-Day Mortality in Intermediate-High and High-Risk Pulmonary Embolism: A Real-World Multidisciplinary Cohort Study.

Özgür Batum … Sibel Doruk

Life (Basel, Switzerland) · 2026

Background

Intermediate-high and high-risk pulmonary embolism (pulmonary embolism) are associated with substantial mortality despite anticoagulation.

Purpose

We aimed to evaluate predictors of 90-day mortality and the impact of reperfusion therapy in patients with intermediate-high and high-risk pulmonary embolism managed within a multidisciplinary Pulmonary Embolism Response Team (Pulmonary Embolism Response Team).

Methods

This retrospective cohort study included 114 consecutive patients with intermediate-high or high-risk acute pulmonary embolism admitted to a tertiary referral center between October 2023 and December 2024.

Results

reperfusion cut 90-day death risk by about 95%

OR by subgroup · 95% CI

More results

The mean age was 68 ± 16 years, and 88% had at least one comorbidity.

Mortality rates were 1% at 24 h, 6% at 7 days, 17% at 30 days, and 25% at 90 days.

More results

In multivariate analysis, hemoglobin ≤ 11.7 g/dL (OR 5.06, 95% CI 1.58-16.17, p = 0.006), sPESI > 2 (OR 4.86, 95% CI 1.49-15.84, p = 0.009), prior stroke (OR 11.59, 95% CI 2.08-64.51, p = 0.005), and high 30-day mortality risk classification (OR 14.14, 95% CI 1.19-167.89, p = 0.036) were independent predictors of mortality.

“

Conclusion · 1 of 3

In this real-world cohort of intermediate-high and high-risk pulmonary embolism, reperfusion therapy was independently associated with lower 90-day mortality and low bleeding risk.

Conclusion · 2 of 3

In addition to established predictors, sPESI retained strong prognostic value beyond its traditional 30-day timeframe.

Conclusion · 3 of 3

These findings support risk-adapted reperfusion strategies guided by multidisciplinary teams and reinforce the role of integrated clinical risk assessment in optimizing outcomes.

Post

Predictors of 90-Day Mortality and the Association of Reperfusion Therapy with 90-Day Mortality in Intermediate-High and High-Risk Pulmonary Embolism: A Real-World Multidisciplinary Cohort Study.

Reperfusion therapy independently associated with lower 90-day mortality in high-risk pulmonary embolism

Related papers